Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are the following:
1. To demonstrate that AMG 223 will produce a statistically significant reduction in serum
phosphorus compared with placebo over a 3 week treatment period in subjects with CKD
receiving dialysis
2. To describe a dose response for AMG 223
3. To evaluate the safety and tolerability of AMG 223